NMRA-335140
Sponsors
Neumora Therapeutics Inc., Neumora Therapeutics, Inc.
Conditions
Major Depressive Disorder
Phase 2
Phase 3
Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder
CompletedNCT06029426
Start: 2023-09-20End: 2025-01-15Updated: 2025-11-26
Study to Assess the Safety and Effectiveness of NMRA-335140-501
TerminatedNCT06029439
Start: 2023-11-10End: 2026-08-17Updated: 2026-09-14
Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive Disorder
CompletedNCT06058039
Start: 2023-12-21End: 2026-06-11Updated: 2026-07-06
Study to Assess the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder
CompletedNCT06058013
Start: 2023-12-20End: 2026-06-17Updated: 2026-07-06
A Phase 3, Randomized, Double blind, Placebo controlled Study to Evaluate the Effects of Oral NMRA-335140 versus Placebo in Participants with Major Depressive Disorder
RecruitingCTIS2023-506335-15-00
Start: 2024-07-18Target: 127Updated: 2025-09-05
Long-term Study to Assess the Safety and Effectiveness of NMRA-335140 in Participants with Major Depressive Disorder
RecruitingCTIS2023-505892-56-00
Start: 2024-09-30Target: 495Updated: 2025-09-10